Skip to Main Content
FIND A CLINIC

Discover beauty that’s true to you

play stop

讓Juvéderm®展現你的獨特光芒

作為全球銷量NO.1的透明質酸療程品牌*1，Juvéderm®喬雅登®致力於讓你擁有專屬的理想效果。

跟據你所選擇的療程，系列內不同產品的效果可持效達9 – 24 個月2-4。一起探索無限可能，發掘獨一無二的美感輪廓！

爲甚麽選擇Juvéderm®？

01_Foundation/Illustration/Natural Copy

效果自然†5,6

Juvéderm®的主要成分是透明質酸7-11，天然存在於皮膚組織†5-6；利用國際專利技術VYCROSS™，使其與肌膚融爲一體，效果更自然12。

01_Foundation/Illustration/Satisfaction Copy

領先全球



作為全球銷量第一的透明質酸品牌*1，Juvéderm®系列能切合你獨特的需求。

01_Foundation/Illustration/Winner Copy

No.1長效13

Juvéderm®療程可持效達9-24 個月2-4，助您保持真我風采。

01_Foundation/Illustration/Calendar Copy

滿意度高‡14

科研實証，超過95％用家對即時效果感到滿意15。

*Based on healthcare professional tracking market research involving over 1,700 healthcare professionals from 16 international markets1
†The open label study evaluated the use of Juvéderm® VOLBELLA with Lidocaine in lip augmentation over a period of 12 months.5
‡Based on FACE-Q Satisfaction with Skin score of 90.8% (N=131) at Month 1. Responses were rated on a 4-point scale (1: very dissatisfied; 4: very satisfied). FACE-Q Satisfaction with Skin score was calculated by summing the responses to the 12 items and converting to a scale score (range: 0–100).17 Study was conducted with Juvéderm® VOLITE without Lidocaine.14 

Juvéderm®用家的蛻變

您的專屬Juvéderm®美感療程

自然豐盈 細緻淡紋19

臉上的細紋皺紋讓人更顯老態。Juvéderm® VOLIFT® 減淡法令紋、木偶紋等表情紋19,20，療程後用家感覺年輕5年以上20。

了解更多

重拾耀眼明眸21

肌膚滋潤度與彈性隨著時間而減少17,18,22,23，令眼周開始鬆弛、出現淚溝及細紋。17,18,24-26

Juvéderm® VOLBELLA® 都可以助您針對眼周的煩惱。21

了解更多

提昇豐盈中面輪廓16

隨年齡增長，臉部輪廓因組織流失而開始下垂17,18。要重拾年輕感，Juvéderm® VOLUMA® 為自然提昇輪廓打好基礎16，獲超過95%用家滿意即時效果15。

了解更多

立體輪廓 側顏立現4

下顎線是締造面臉美學的關鍵，對整體輪廓有協調美觀的重要作用。Juvéderm® VOLUX™

專為立體輪廓而設，展示更立體的下顎綫及下巴4，令面型比例更理想。

了解更多

尋找適合您的診所

Materials provided by Allergan Aesthetics, an AbbVie company. This content is intended for [insert country name] adult (>18yrs) audience only. You should always consult a healthcare professional to help you decide if products in the Allergan Aesthetics facial filler range is right for you and provide you with a full list of side effects. Adverse events should be reported to Allergan Aesthetics, an AbbVie company [insert local contact details for AE reporting]. Models treated with products in the Allergan Aesthetics facial filler range. Actual results may vary. Images are for illustrative purposes only. © 2022 AbbVie. All rights reserved. All trademarks are the property of their respective owners. Please note that as per the Medical Device Regulation requirements, a summary of safety information is mandatory for fillers. Countries should refer to their local DFU for a full list of side effects.

References:

1. Allergan Aesthetics. Data on File. REF-108642. JUVÉDERM®, the world’s leading brand of hyaluronic acid facial fillers claim;
2. Jones D, Murphy DK. Dermatol Surg 2013; 39:1602–1612;
3. Niforos F et al. Clin Cosmet Investig Dermatol 2019; 12:791–798;
4. Ogilvie P et al. Aesthet Surg J. 2020 Aug 14;40(9):NP499-NP510;
5. Eccleston D, Murphy DK. Clin Cosmet Investig Dermatol 2012; 5:167–172;
6. Goodman GJ et al. Plast Reconstr Surg 2015; 136:139–148;
7. Juvéderm® VOLUX DFU. 73651JR10. Revision 2019.09.09;
8. Juvéderm® VOLUMA with lidocaine DFU. 73650JR10. Revision 2019-09-09;
9. Juvéderm® VOLIFT with lidocaine DFU. 73652JR10. Revision 2019-09-09;
10. Juvéderm® VOLBELLA with lidocaine DFU. 73363JT10. Revision 2020-07-10;
11. Juvéderm® VOLITE DFU. 73655JR10. Revision 2019-09-09;
12. Hee CK et al. Dermatol Surg. 2015;41(Suppl 1):S373–81;
13. Allergan Aesthetics. Data on File. REF-74194. VYCROSS® – longest duration of hyaluronic acid facial filler in clinical trials. Jan 2020;
14. Ogilvie P et al. J Cosmet Dermatol 2020; 19:1065–1070;
15. Philipp-Dormston WG et al. J Cosmet Laser Ther. 2014;16:171–79;
16. De Maio M, et al. Plast Reconstr Surg. 2017 Oct;140(4):540e-550e;
17. Shin JW et al. Int J Mol Sci 2019; 20;
18. Swift A et al. Aesthet Surg J 2020; 41:1107–1119;
19. Dayan S et al. Aesthet Surg J. 2020 Jun 15;40(7):767-777;
20. Ogilvie P et al. Dermatol Surg. 2020 Mar;46(3):376-385;
21. Niforos F et al. Dermatol Surg 2017; 43:1271–1280;
22. Allemann IB, Baumann L. Clin Interv Aging 2008; 3:629–634;
23. Zhang S, Duan E. Cell Transplant 2018; 27:729–738;
24. Brandt FS, Cazzaniga A. Clin Interv Aging 2008; 3:153–159;
25. Fundarò S et al. Med Dent Res 2018; 1:1–7;
26. Roh MR, Chung KY. Dermatol Surg 2009; 35:1163–1171.